Eric M. Dube - Aug 31, 2023 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role: Chief Executive Officer, Director
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol: TVTX
Transactions as of: Aug 31, 2023
Transactions value $: -$65,533
Form type: 4
Date filed: 9/5/2023, 08:10 PM
Previous filing: Jun 8, 2023
Next filing: Jan 25, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TVTX	Common Stock	Award	$0	+9.9K	+4.17%	$0.00	247K	Aug 31, 2023	Direct	F1
transaction	TVTX	Common Stock	Sale	-$65.5K	-4.46K	-1.8%	$14.71	243K	Sep 5, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 31, 2020, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock. On August 31, 2023, PRSUs vested upon the closing of the sale of the Company's bile acid portfolio following a modification approved by the Compensation Committee for a reduced number of shares to vest under PRSUs originally granted on January 31, 2020 that were to vest upon specified clinical or regulatory milestones related to the Company's bile acid portfolio.
F2	The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

Content

On January 31, 2020, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock. On August 31, 2023, PRSUs vested upon the closing of the sale of the Company's bile acid portfolio following a modification approved by the Compensation Committee for a reduced number of shares to vest under PRSUs originally granted on January 31, 2020 that were to vest upon specified clinical or regulatory milestones related to the Company's bile acid portfolio.

The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.